Market research
337.F Corbus Pharmaceuticals Holdings, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 2.05
- Dividend yield
- 0.0%
- Beta
- 2.14
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US21833P1030
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 2.05
- Dividend yield
- 0.0%
- Beta
- 2.14
About
About Corbus Pharmaceuticals Holdings, Inc
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 337.F discussion.
5 years, 5 months ago
Corbus Pharmaceuticals Holdings, Inc is currently in a long term downtrend where the price is trading 1.1% below its 200 day moving average.
From a valuation standpoint, the stock is 96.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 40.5.
Corbus Pharmaceuticals Holdings, Inc's total revenue sank by 74.4% to $658K since the same quarter in the previous year.
Its net income has increased by 67.6% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.4% to $-18M since the same quarter in the previous year.
Based on the above factors, Corbus Pharmaceuticals Holdings, Inc gets an overall score of 3/5.